News about 'r&d'

19 May 2010
Professor of Microbiology and Immunology and of Molecular Genetics, Albert Einstein College of Medicine. This video was recorded on November 13, 2009 at Johns Hopkins University. Dr. Bill Jacobs Jacobs moved to Albert Einstein College of Medicine in 1985 to become a postdoc with Barry Bloom, who...
18 May 2010
Global tuberculosis drug development pipeline: the need and the reality by Zhenkun Ma, Christian Lienhardt, Helen McIlleron, Andrew J Nunn, Xiexiu Wang Today, The Lancet published a series of articles on tuberculosis, which highlights the continued devastating global impact of this disease, the...
17 May 2010
This post originally appeared on SciDev.net The patent pool may boost research into neglected diseases, such as guinea worm infection. CDC PHIL (8224) by Linda Nordling 10 May 2010 [CAPE TOWN] An industry-led ‘patent pool’, set up last year to target neglected diseases, has finally yielded some...
12 May 2010
Dr. Gyanu Lamichhane is Assistant Professor, Division of Infectious Diseases at the Johns Hopkins University Center for Tuberculosis Research Labs. This interview was conducted at JHU on November 13, 2009. The following bio is excerpted from this bio sketch (.pdf – 80kb) , which includes a list of...
9 May 2010
TBVI The University of Zaragoza (Spain), together with TuBerculosis Vaccine Initiative (TBVI) and the Spanish Fundación Ramón Areces, presents an international symposium: “Research and Development of new Tuberculosis Vaccines”. This symposium will be held on 3 and 4 June in Zaragoza, Spain. During...
26 Apr 2010
How much does the nose know about TB? In a post a few weeks ago , we highlighted HeroRats , African-pouch rats, and their use for TB diagnoses. As described in that article, these rats are trained to distinguish positive TB samples verses negative TB samples presumably due to the release of...
21 Apr 2010
Dr. Denis Mitchison in the lab When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. For more than half a century, Dr. Mitchison has been dedicated to discovering new treatments for tuberculosis. Recently...
19 Apr 2010
Despite the massive need for new TB drugs, the commercial viability of the TB drug market has long been viewed as questionable at best. Reports suggest that there is a substantial market that will grow year-over-year, though there is no firm conclusion about its commercial viability. The first...
14 Apr 2010
Dr. Denis Mitchison in the lab When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. For more than half a century, Dr. Mitchison has been dedicated to discovering new treatments for tuberculosis. Recently...
12 Apr 2010
NYAS On April 6 th , the New York Academy of Sciences hosted a mini-symposium entitled ‘Tuberculosis: Novel Therapies through Knowledge of the Genetics of the Causative Agent.’ The five research scientists who presented were: William R. Jacobs, Jr . (Albert Einstein College of Medicine),...
7 Apr 2010
Dr. Denis Mitchison in the lab When you think of true pioneers in research and development for the treatment of infectious diseases, Dr. Dennis Mitchison is sure to come to mind. Born on September 6, 1916, Dr. Mitchison has had a long career dedicated to treating tuberculosis. After qualifying in...
5 Apr 2010
Many antibiotics used today to fight and control M. tb infection target cell wall synthesis or DNA replication, and related pathogen growth mechanisms. A recent report by Zhou et al. in PNAS at the beginning of year, suggested an alternate mechanism for M. tb elimination; targeting MptpB, a...
24 Mar 2010
CPTR could deliver a new TB regimen in just 6 years as opposed to 24 After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB. Many...
22 Mar 2010
NYAS In more than 10 years since the sequence of the Mycobacterium tuberculosis genome was published, the genetic information of the pathogen and genetic tools have shifted the emphasis of TB drug research. This symposium highlights how they are utilized in the quest for novel TB regimens. This...
17 Mar 2010
Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and...

Pages